Treatment with once-weekly semaglutide 2.4mg improves cardiometabolic risk factors in adults with overweight/obesity and type 2 diabetes: STEP 2 Post-hosc Analysis.
Obesity is an independent risk factor for cardiovascular diseases. Kushner RF and colleagues have conducted research under the title “Treatment with once-weekly semaglutide 2.4mg improves cardiometabolic risk factors in adults with overweight/obesity and type 2 diabetes: STEP 2 Post-hoc Analysis”. The findings of this study are given below:
Objective:
To investigate the effect of semaglutide 2.4 mg vs. Placebo (PBO) or semaglutide 1.0mg on developing cardiometabolic risk in STEP 2.
Method:
1210 overweight/obese adults with type 2 diabetes were included in this double-blind, placebo-controlled trial. The participants were randomly assigned in 1:1:1 to receive once-weekly semaglutide 2.4 mg, 1.0 mg, or PBO for 68 weeks. The primary outcome included a percentage change in body weight (BW). Change in cardiometabolic risk factor was a secondary outcome.
Findings:
The study found improved cardiometabolic parameters including HbA1c, waist circumference, level of triglyceride, systolic blood pressure, C-reactive protein, fasting plasma glucose, and fasting insulin in semaglutide 2.4 mg group as compare to PBO. Similar improvements were observed with semaglutide 1.0 mg except for changes in waist circumference and BW.
Hence, the study supports the use of semaglutide 2.4mg for outcomes beyond BW loss.
Image Credit : Background photo created by kjpargeter – www.freepik.com